| Prevention |
By prior immunization with available smallpox vaccines |
|
1. JYNNEOS™ (MVA-BN, IMAVAMUNE, IMVANEX) |
|
2. ACAM 2000® |
|
3. Newer APSV (Avantis Pasteur Smallpox Vaccine) |
| Prophylaxis |
1. Pre-exposure: Vaccinating select people at risk for occupational exposure. |
|
2. Post-exposure: Vaccination within 4 d of exposure to the virus to prevent or minimize the development of the disease. |
| Antiviral therapy |
1. Tecovirimat: (oral or intravenous) Adults 600 mg, twice daily; children 13-25 kg 200 mg, twice daily; children 25-40 kg, 400 mg twice daily. The duration of treatment is 14 d. |
|
2. Brincidofovir: (Oral suspension) Adults (>48 kg) 200 mg, once weekly for two doses; children (>10 kg) 4 mg/kg, once weekly for two doses. |
|
3. Cidofovir: (Intravenous) 5 mg/kg, once weekly for 2 wk, followed by 5 mg/kg, once every other week. |
|
4. Vaccinia immune globulins (intravenous): 6000 U/kg as soon as Symptoms appear. Repeat dose required based on response to Treatment and severity of symptoms. |
